Regulatory filing 📈 Stocks 🌍 United States

Creative Medical Technology Receives Nasdaq Deficiency Notice for CELZ

Creative Medical Technology faces a Nasdaq compliance deadline of May 10, 2027, after its stock price remained below $1.00 for 30 consecutive business days, triggering a deficiency notice.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 1 Bearish, 0 Neutral. Strongest signal: CELZ ↓ 4/10 (75% confidence).

📊 Affected Assets (1)

CELZ
Bearish 🤖 75%
📅 Short-term 🌍 US · Explicit

On November 10, 2026 the company received a Nasdaq deficiency notice because its closing bid price was below $1.00 for 30 consecutive business days. Delisting is not immediate: the company has a 180-day grace period until May 10, 2027 to regain compliance, plus a possible second 180-day period. The notice signals a sub-$1 stock price and dilution/reverse-split risk, but no near-term listing change.

Catalysts
  • ▼ Nasdaq minimum bid price deficiency letter received November 10, 2026
  • ▼ 180-day compliance deadline of May 10, 2027; must close at $1.00 or higher for ten consecutive business days
Risk Factors
  • ▲ Notice has no immediate impact on the Nasdaq listing
  • ▲ Possible second 180-day grace period if all other initial listing standards are met

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Creative Medical Technology received a Nasdaq deficiency notice on November 10, 2026, for failing to meet the $1.00 minimum bid price requirement.
  • The company has a 180-day grace period ending May 10, 2027, to regain compliance by maintaining a $1.00 closing price for ten consecutive business days.
  • The notice has no immediate impact on the company's listing on The Nasdaq Stock Market.
  • Management is considering options to regain compliance, which may include a reverse stock split.

📝 Executive Summary

Creative Medical Technology Holdings, Inc. disclosed on November 13, 2026, that it received a Nasdaq deficiency notice on November 10. The company failed to maintain the required $1.00 minimum closing bid price for 30 consecutive business days. The firm has until May 10, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2).

❓ FAQ

Is Creative Medical Technology being delisted from Nasdaq now?

No. The November 10, 2026 letter states the listing is not immediately affected. The company has until May 10, 2027 to get its closing bid price back to $1.00 or above for at least ten consecutive business days, and may qualify for an additional 180-day grace period.

Why did the company receive this notice?

Its common stock closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 bid price.